Created in 1974, the primary purpose of the MAPI Group remains to conceive and implement studies with the objective of evaluating drugs, and to deploy simultaneously the expertise required for each type of study and the necessary organization to collect and analyze all vital data.
A full range of expertise in the following sectors:
|
• Phase IV Clinical Trials • Registries & Observational studies • Risk Management Plan • Direct Patient Management • Signal Detection
|
 STRATEGIC CONSULTING
• Market Access • Patient Reported Outcomes • Pharmaco-epidemiology • Regulatory & Pharmaceutical Affairs |
|
•Patient-reported and clinical assessments for appropriate cross-cultural use and interpretation |
To learn more about our services, click on the individual service pages on your left.
Version française 